Drug Information

Drug General Information
Drug ID
D03RZV
Former ID
DAP000477
Drug Name
Tolazoline
Synonyms
Artonil; Benzalolin; Benzazoline; Benzidazol; Benzolin; Benzylimidazoline; Divascol; Imidalin; Imidaline; Kasimid;Lambril; Olitensol; Peripherine; Phenylmethylimidazoline; Prefaxil; Pridazole; Priscol; Priscoline; Tolazolin; Tolazolina; Tolazolinum; Vasimid; Vasodil; Vasodilatan; Dilatol ASI; Tolazine [veterinary]; Tolazoline Monohydrochloride; Ciba 3259; Benzolin (VAN); Benzolin (vasodilator); Tolazine [veterinary] (TN); Tolazolina [INN-Spanish]; Tolazoline (INN); Tolazoline [INN:BAN]; Tolazolinum [INN-Latin]; Benzolin (vasodilator) (VAN); 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)-(9CI); 2-(phenylmethyl)-4,5-dihydro-1H-imidazole; 2-BENZYL-4,5-IMIDAZOLINE HCl; 2-Benzyl-2-imidazoline; 2-Benzyl-4,5-dihydro-1H-imidazole; 2-Benzyl-4,5-imidazoline; 2-Benzylimidazoline; 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole
Drug Type
Small molecular drug
Indication Peripheral vasoconstriction; Pulmonary hypertension [ICD9: 443, 416; ICD10:I73, I27.0, I27.2] Approved [538395], [542333], [551871]
Therapeutic Class
Vasodilator Agents
Structure
Download
2D MOL

3D MOL
Formula
C10H12N2
InChI
InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)
InChIKey
JIVZKJJQOZQXQB-UHFFFAOYSA-N
CAS Number
CAS 59-98-3
PubChem Compound ID
5504
PubChem Substance ID
9356, 92381, 608291, 5657916, 8153384, 10529062, 11112156, 11335503, 11360742, 11363625, 11366187, 11368749, 11371668, 11373932, 11376911, 11461714, 11466088, 11467208, 11484724, 11485876, 11489020, 11490410, 11492172, 11494545, 15146988, 24857660, 28418847, 29214781, 29224547, 46505641, 47440163, 47515229, 47588908, 47736383, 47885316, 48035019, 48334401, 48416642, 49698326, 49980604, 50100379, 50100380, 50711245, 51072562, 57322812, 85209661, 85787924, 96025298, 103203764, 103936644
ChEBI ID
ChEBI:28502
SuperDrug ATC ID
C04AB02; M02AX02
SuperDrug CAS ID
cas=000059983
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Antagonist [536163]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 538395FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 006403.
Ref 542333(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7310).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 536163Comparative effects of tolazoline and nitroprusside on human isolated radial artery. Ann Thorac Surg. 2006 Jan;81(1):125-31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.